abstract |
The present invention relates to new compounds of formula (I) (See Formula) that are capable of inhibiting one or more kinases, especially SYK (spleen tyrosine kinase), LRRK2 (leucine-rich repeat kinase 2) and / or MYLK (myosin light chain kinase) or its mutants. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin diseases, eye diseases, infectious diseases and related diseases With hormones |